进展期胃癌的外科治疗：一个不断发展的问题。
Surgical management of advanced gastric cancer: An evolving issue.
作者信息
Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, De Luca R, Petrioli R, Martinotti M, Generali D, Marrelli D, Di Martino N, Roviello F
机构信息
General, Minimally Invasive and Robotic Surgery, Department of Surgery, "San Matteo degli Infermi" Hospital, ASL Umbria 2, Via Loreto 3, 06049, Spoleto PG, Italy.
Department of Medical, Surgical and Neuroscience; Unit of General and Minimally Invasive Surgery, University of Siena, Viale Bracci 11, 53100, Italy.
出版信息
Eur J Surg Oncol. 2016 Jan;42(1):18-27. doi: 10.1016/j.ejso.2015.10.016. Epub 2015 Nov 14.
Worldwide, gastric cancer represents the fifth most common cancer and the third leading cause of cancer deaths. Although the overall 5-year survival for resectable disease was more than 70% in Japan due to the implementation of screening programs resulting in detection of disease at earlier stages, in Western countries more than two thirds of gastric cancers are usually diagnosed in advanced stages reporting a 5-year survival rate of only 25.7%. Anyway surgical resection with extended lymph node dissection remains the only curative therapy for non-metastatic advanced gastric cancer, while neoadjuvant and adjuvant chemotherapies can improve the outcomes aimed at the reduction of recurrence and extension of survival. High-quality research and advances in technologies have contributed to well define the oncological outcomes and have stimulated many clinical studies testing multimodality managements in the advanced disease setting. This review article aims to outline and discuss open issues in current surgical management of advanced gastric cancer.
在全球范围内，胃癌是第五大常见癌症，也是癌症死亡的第三大主要原因。尽管由于实施筛查计划，日本可切除疾病的总体5年生存率超过70%，这使得疾病能够在早期被发现，但在西方国家，超过三分之二的胃癌通常在晚期才被诊断出来，其5年生存率仅为25.7%。无论如何，扩大淋巴结清扫的手术切除仍然是治疗非转移性晚期胃癌的唯一治愈性疗法，而新辅助化疗和辅助化疗可以改善治疗效果，旨在降低复发率并延长生存期。高质量的研究和技术进步有助于明确肿瘤学治疗效果，并激发了许多在晚期疾病背景下测试多模式管理的临床研究。这篇综述文章旨在概述和讨论晚期胃癌当前外科治疗中存在的未解决问题。
Zotero 插件